

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- |                                     |  |
|-------------------------------------|--|
| n/a                                 | Confirmed  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated  |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

|                 |   |
|-----------------|---|
| Data collection | <p>All cryo-EM data were collected using AutoEMation v2 or SerialEM 3.8.1 or EPU (Thermo Fisher), defocus values were estimated using Gctf 7 or cryoSPARC.</p> <p>All electrophysiological data were collected using an EPC10-USB amplifier with Patchmaster software v2*90.2.</p>  |
| Data analysis   | <p>All collected cryo-EM data were processed using MotionCor2 v1 or Warp v1.0.9, cryoSPARC v3.3.2.</p> <p>Map and model refinement were processed with UCSF-Chimera v1.14, COOT v0.9.3 and PHENIX v1.18.</p> <p>Electrophysiology data were acquired using Patchmaster2019 and processed using Origin 2019b and GraphPad Prism 8.0.2;</p> <p>Molecular docking simulation was performed using Schrödinger Suite 2018-1, Glide program with the extra-precision docking method (Glide XP). The initial small molecule structures were generated and optimized using LigPrep program14 with the OPLS3 force field,15 while the protein structure was processed using the default setting within Protein Preparation Wizard with the coordinates of the Nav1.7-BPV complex as input.</p> <p>All figures were analyzed and prepared using ChimeraX v1.1 and GraphPad Prism 8.0.2.</p> |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The sequences of human Nav1.7,  $\beta 1$  and  $\beta 2$  are available in the following links: Nav1.7 (UniProtID:Q15858): <https://www.uniprot.org/uniprotkb/Q15858/entry>;  $\beta 1$  (UniProtID:Q07699): <https://www.uniprot.org/uniprotkb/Q07699/entry>;  $\beta 2$  (UniProtID:O60939): <https://www.uniprot.org/uniprotkb/O60939/entry>. The cryo-EM maps have been deposited in the Electron Microscopy Data Bank under accession code EMD-35193 [<https://www.emdataresource.org/EMD-35193>] (Nav1.7-BPV), EMD-40238 [<https://www.emdataresource.org/EMD-40238>] (Nav1.7-LCM), EMD-40239 [<https://www.emdataresource.org/EMD-40239>] (Nav1.7-CBZ), EMD-35197 [<https://www.emdataresource.org/EMD-35197>] (Nav1.7-VPC), EMD-35975 [<https://www.emdataresource.org/EMD-35975>] (Nav1.7-HDA), EMD-35198 [<https://www.emdataresource.org/EMD-35198>] (Nav1.7-VXT), and EMD-35194 [<https://www.emdataresource.org/EMD-35194>] (Nav1.7-PF-05089771). The coordinates have been in the RCSB Protein Data Bank (PDB) under accession code 8I5B [<https://doi.org/10.2210/pdb8I5B/pdb>] (Nav1.7-BPV), 8S9B [<https://doi.org/10.2210/pdb8S9B/pdb>] (Nav1.7-LCM), 8S9C [<https://doi.org/10.2210/pdb8S9C/pdb>] (Nav1.7-CBZ), 8I5X [<https://doi.org/10.2210/pdb8I5X/pdb>] (Nav1.7-VPC), 8J4F [<https://doi.org/10.2210/pdb8J4F/pdb>] (Nav1.7-HDA), 8I5Y [<https://doi.org/10.2210/pdb8I5Y/pdb>] (Nav1.7-VXT), and 8I5G [<https://doi.org/10.2210/pdb8I5G/pdb>] (Nav1.7-PF-05089771), respectively. Previously solved structures mentioned in this study are under the accession codes in PDB: 7W9K [<https://doi.org/10.2210/pdb7W9K/pdb>]; 6J8J [<https://doi.org/10.2210/pdb6J8J/pdb>]; 6J8I [<https://doi.org/10.2210/pdb6J8I/pdb>]; 6J8E [<https://doi.org/10.2210/pdb6J8E/pdb>]; 7W9M [<https://doi.org/10.2210/pdb7W9M/pdb>]; 7W9T [<https://doi.org/10.2210/pdb7W9T/pdb>]; 7W9P [<https://doi.org/10.2210/pdb7W9P/pdb>]; 5EK0 [<https://doi.org/10.2210/pdb5EK0/pdb>]; 7XMF [<https://doi.org/10.2210/pdb7XMF/pdb>]; 7XMG [<https://doi.org/10.2210/pdb7XMG/pdb>]; 7XM9 [<https://doi.org/10.2210/pdb7XM9/pdb>]; 6LQA [<https://doi.org/10.2210/pdb6LQA/pdb>]; 7FBS [<https://doi.org/10.2210/pdb7FBS/pdb>]; 8G1A [<https://doi.org/10.2210/pdb8G1A/pdb>]. The source data underlying Figure 1d, Supplementary Fig. 2a-b and 4 are provided as a Source Data file.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

|  |   |
|--|---|
| Reporting on sex and gender  | n/a. Human research participants were not involved in this study. |
| Reporting on race, ethnicity, or other socially relevant groupings | n/a. Human research participants were not involved in this study. |
| Population characteristics   | n/a. Human research participants were not involved in this study. |
| Recruitment  | n/a. Human research participants were not involved in this study. |
| Ethics oversight   | n/a. Human research participants were not involved in this study. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

|                 |   |
|-----------------|---|
| Sample size     | No statistical method was conducted to determine sample sizes. The cryo-EM data size was determined by microscope available time and the sample quantity. The cryo-EM data were sufficient to obtain high resolution maps for model building. For electrophysiological experiments, 4 or more cells/patches were conducted for each trial.  |
| Data exclusions | For cryo-EM analysis, micrographs with low CTF fitting resolution were excluded, only high resolution and homogeneous particles were retained.  |
| Replication     | General protocols were conducted to verify the reproducibility of experimental results. For the ion current measurement, each experiment data have been successfully repeated with at least three batches of samples and all results were similar. All attempts at replication were successful. The cryo-EM analysis of different drug-bound Nav1.7s are performed independently. |
| Randomization   | The randomization is not relevant to our study. Because our experiments only studied cryo-EM structures, electrophysiological properties of WT human Nav1.7 protein.  |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a                                 | Involved in the study                                     |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies                       |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms      |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data                    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Plants                           |

### Methods

| n/a                                 | Involved in the study                           |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq               |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry         |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

|  |  |
|--|--|
| Cell line source(s)  | HEK293F (Invitrogen); HEK293T (Invitrogen)                                     |
| Authentication   | No further authentication was performed for commercially available cell lines. |
| Mycoplasma contamination   | The cell lines were not tested for mycoplasma contamination.                   |
| Commonly misidentified lines<br>(See <a href="#">ICLAC</a> register) | No commonly misidentified lines were used in this study.                       |